Menu
Back to Journals » Drug, Healthcare and Patient Safety » Volume 10
Long-term safety profile of tolvaptan in autosomal dominant polycystic kidney disease patients: TEMPO Extension Japan Trial [Corrigendum]
Authors Muto S, Okada T , Yasuda M, Tsubouchi H, Nakajima K, Horie S
Received 29 May 2018
Accepted for publication 29 May 2018
Published 16 July 2018 Volume 2018:10 Pages 67—68
Muto S, Okada T, Yasuda M, et al. Drug Healthc Patient Saf. 2017;9:93–104.
On page 97, ‘Discussion’ section, lines 10–13, left column, the sentence: ‘Similarly, placebo patients who crossed over onto active treatment discontinued at a similar rate (24.0%), while those who continued on tolvaptan treatment discontinued at a much lower rate (11.8%)’ should read: ‘Similarly, placebo patients who crossed over onto active treatment discontinued at a similar rate (26.0%), while those who continued on tolvaptan treatment discontinued at a much lower rate (10.6%)’. On page 101, Figure 6, the number of patients of ‘Completed trial’ in the TEMPO Extension Japan trial should be revised from ‘n=75’ to ‘n=76’, and ‘Withdrawal rate’ should also be revised from ‘11.8%’ to ‘10.6%’ in the allocated to tolvaptan in TEMPO 3:4 trial. The number of patients of ‘Completed trial’ in TEMPO Extension Japan trial should be revised from ‘n=38’ to ‘n=37’, and ‘Withdrawal rate’ should also be revised from ‘24.0%’ to ‘26.0%’ in the allocated to placebo in TEMPO 3:4 trial.
Read the original article.
© 2018 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.